💥Join UPSC 2027,2028 Mentorship (July Batch) + XFactor Notes & Microthemes PDF

Subject: Science and Technology

  • Gaganyaan: ISRO Conducts First SOLVE Ground Test

    Why in News?

    ISRO successfully conducted the first ground test of the Sub-Orbital Launch Vehicle for Experiments (SOLVE) solid motor at the Satish Dhawan Space Centre, Sriharikota, for the Gaganyaan Mission.

    What is SOLVE?

    • SOLVE (Sub-Orbital Launch Vehicle for Experiments) is a solid motor-based test vehicle developed by ISRO.
    • It is designed to validate the Crew Module’s parachute-based deceleration system under different mission conditions.
    • A key component for future Gaganyaan Test Missions.

    Key Features

    • Carries the Crew Module to an altitude of 10 to 17 km.
    • After separation, a series of 10 parachutes slows the Crew Module before sea splashdown.
    • Solid motor derived from the PSLV Strap-on Motor with modifications such as:
      • Slow burn-rate propellant.
      • Straight nozzle with Secondary Injection Thrust Vector Control (SITVC).

    Significance

    • Validates the Crew Module recovery system.
    • Provides flexibility to simulate different mission scenarios.
    • Supports upcoming uncrewed and crewed Gaganyaan missions.

    About Gaganyaan Mission

    • India’s first human spaceflight mission.
    • Objective: Demonstrate the capability to send three astronauts to a 400 km Low Earth Orbit (LEO) for about three days and safely recover them in Indian waters.
    • Implemented by ISRO.

    [2025] Consider the following space missions:
    I. Axiom-4
    II. SpaDeX
    III. Gaganyaan
    How many of the space missions given above encourage and support microgravity research?

    [A] Only one

    [B] Only two

    [C] All the three

    [D] None

  • Antibiotics to creams: The perils of combination meds

    Why in the News?

    The government has banned 16 fixed-dose combination (FDC) drugs, including antibiotic and dermatological formulations, for lacking scientific justification. The ban exposes that many combinations survived in the market for years on commercial convenience rather than clinical evidence. This exposed patients to unnecessary risk and worsening antimicrobial resistance.

    What triggered the ban on 16 fixed-dose combination drugs?

    1. Scope of the ban: The government banned 16 FDC drugs, covering antibiotic combinations and dermatological products containing aloe vera and other herbal ingredients.
    2. Stated ground for the ban: The banned products lack scientific justification for their claimed amplified benefit.
    3. Definition of the underlying problem: An FDC is irrational when its ingredients have no scientifically established rationale for being combined in a single product.
    4. Test for rationality: Each component must contribute meaningfully to the intended therapeutic effect, have compatible pharmacological properties, and demonstrate additional clinical benefit compared to using the medicines individually.
    5. Evidentiary gap: In many banned cases, no clinical trial evidence supports the combination.

    Why does a combination drug’s long presence in the market not establish its scientific validity?

    1. Central tension: Longevity in the market does not establish scientific validity.
    2. Case in point: Many banned dermatological combinations contained aloe vera extracts, vitamin E, jojoba oil, olive oil, tea tree oil, and other moisturising or herbal components, sold for years despite lacking evidence.
    3. The real question: Whether combining these ingredients produces a measurable clinical benefit compared with using them individually.
    4. Evidentiary standard: Robust scientific evidence demonstrating superior efficacy is lacking for many such products.
    5. Illustrative failure: Combination creams pairing a steroid and an antifungal give temporary relief from itching and redness because the steroid suppresses the skin’s local immune response, but this same suppression allows the underlying fungal infection to worsen, spread, or become resistant to treatment.
    6. Governance root cause: In the pre-reform period, thousands of FDCs were approved by state licensing authorities without central review, exploiting a regulatory loophole in the Drugs & Cosmetics Act. 

    What do specific banned combinations reveal about irrational drug design?

    1. Amoxicillin + serratiopeptidase: Serratiopeptidase is acid-labile, meaning it degrades in the stomach before reaching the bloodstream.
    2. No demonstrated benefit: No evidence shows that adequate therapeutic concentrations of serratiopeptidase reach infected tissues.
    3. No trial support: No peer-reviewed randomised controlled trial has shown that adding serratiopeptidase improves bacterial clearance, increases cure rates, or reduces the antibiotic dose required.
    4. Norflox TZ (norfloxacin + tinidazole): Tinidazole is pointless for purely bacterial diarrhoea; norfloxacin provides zero benefit for amoebic dysentery. Patients rarely have both infections simultaneously, yet exposure to both drugs unnecessarily promotes bacterial resistance.
    5. Augmentin 625 (amoxicillin + clavulanic acid): Clavulanic acid blocks the enzyme that resistant bacteria use to destroy amoxicillin, but is useless if the infecting bacteria are not resistant.
    6. Guideline recognition: No major treatment guideline currently recommends serratiopeptidase as an antibiotic adjunct for managing infections.

    What does global regulatory practice show about evaluating combination drugs?

    1. United States: All FDCs require a new drug application supported by clinical evidence of superiority or convenience over the individual components.
    2. World Health Organization: The WHO explicitly cautions against irrational FDCs; only combinations on its essential medicines list are treated as evidence-based.
    3. European Union: FDCs undergo full scientific review and can be justified only with supporting clinical data.
    4. India (pre-reform): Thousands of FDCs were approved by state licensing authorities without central review, exploiting a loophole in the Drugs & Cosmetics Act.
    5. India (post-2016): Around 6,000 FDCs were reviewed by a central committee, and bans have been initiated in phases since.

    How do irrational antibiotic combinations contribute to antimicrobial resistance?

    1. Marketing effect: When combinations are marketed as more effective without sufficient evidence, they encourage unnecessary and prolonged antibiotic use.
    2. Exposure pathway: This increases antibiotic exposure in the community and creates selective pressure on bacteria.
    3. Resistance mechanism: Selective pressure allows resistant organisms to survive and multiply.
    4. Policy implication: From a public health perspective, antibiotic use should be as targeted and evidence-based as possible.
    5. Scale of the underlying problem: AMR is a growing public health problem because bacteria, viruses, fungi, and parasites no longer respond to the medicines designed to kill them.

    What risks do patients face from irrational FDCs?

    1. Unnecessary drug exposure: Patients face an increased possibility of adverse effects, drug interactions, and allergic reactions.
    2. Dose inflexibility: Fixed combinations make it difficult for doctors to adjust the dose of individual ingredients to a patient’s needs.
    3. Titration failure: If a doctor wants to increase the dose of one medication, this cannot be done without also increasing the other.
    4. Diagnostic masking: Combination drugs can mask an underlying complication, reducing precision in treatment.

    What should patients, doctors, and pharmacists do now that these products are banned?

    1. Patient understanding: A medicine with multiple ingredients is not necessarily more effective than a targeted treatment.
    2. Preferred alternative: A simpler medicine supported by strong evidence is often the safer and more effective option.
    3. Continuity of care: Patients using banned products should consult their doctor about alternatives; stopping an irrational FDC does not mean stopping treatment.
    4. Doctor’s role: The focus should be on de-escalating patients to rational therapies supported by evidence.
    5. Pharmacist’s role: Pharmacists should track the regulator’s list of banned FDCs, flag irrational prescriptions, and educate patients on available alternatives.
    6. Related caution- vitamins and probiotics with antibiotics: There is no definitive evidence that pairing them with antibiotics is indispensable; probiotics may be advised case-by-case, and vitamins are generally unnecessary for a short antibiotic course except in vulnerable groups.

    Conclusion

    A drug combination’s survival in the market does not establish its scientific validity; irrational FDCs persisted because regulatory review was historically weak, not because evidence supported them. Regulatory decisions on combination drugs must rest on clinical trial evidence and risk-benefit assessment rather than duration of commercial availability. Continuous post-marketing surveillance is needed to identify and withdraw irrational combinations before they further entrench antimicrobial resistance.

    PYQ Relevance

    [UPSC 2013] What do you understand by Fixed Dose Drug Combinations (FDCs)? Discuss their merits and demerits.

    Linkage: The PYQ asks for a direct conceptual and evaluative treatment of FDCs. The article supplies current, case-specific demerits (Norflox TZ, Augmentin 625, serratiopeptidase, dermatological creams) that can update and substantiate this answer.

  • India’s First Privately Developed Orbital-Class Rocket Vikram-1 Set for Launch

    Why in News?

    India’s first privately developed orbital-class launch vehicle, Vikram-1, developed by Skyroot Aerospace, is scheduled for its maiden mission, Mission Aagaman, with a launch window from 12 July to 4 August 2026 from the Satish Dhawan Space Centre, Sriharikota.

    What is Mission Aagaman?

    • Mission Aagaman (“Arrival”) is the first orbital test flight of Vikram-1.
    • It follows the successful launch of Vikram-S, India’s first private suborbital rocket (18 November 2022).
    • It is a partially commercial mission carrying payloads from domestic and international customers.
    • The mission aims to validate critical flight systems before full commercial operations.

    About Vikram-1

    • India’s first privately developed orbital-class launch vehicle.
    • Developed by Skyroot Aerospace, Hyderabad.
    • Height: About 24 metres (seven-storey tall).
    • Configuration: Multi-stage launch vehicle.
    • Payload Capacity: Up to 350 kg to Low Earth Orbit (LEO).
    • Target Orbit: 450 km altitude with 60° orbital inclination.
    • Built using an all-carbon composite structure for lightweight construction.
    • Powered by:
      • High-thrust solid rocket boosters.
      • In-house liquid propulsion systems.
      • 3D-printed rocket engines, enabling faster and cost-effective manufacturing.
    • Designed for rapid manufacturing and high launch frequency.

    Objectives of the Maiden Flight

    • Validate: Propulsion systems. Stage separation. Guidance, Navigation and Control (GNC). Overall vehicle performance.
    • Collect real-time in-flight data that cannot be fully simulated during ground testing.
    • Lay the foundation for high-cadence commercial satellite launches.

    [2026] Consider the following statements with regard to involvement of private entities in India’s space programme :
    1. The Indian National Space Promotion and Authorisation Centre (IN-SPACe) is an autonomous agency formed to facilitate participation of private entities.
    2. Agnikul Cosmos launched the world’s first flight using 3D-printed rocket engine.
    3. Skyroot Aerospace has developed liquid fuel for GSLV.
    Which of the statements given above is/are correct?

    [A] 1 only

    [B] 2 and 3 only

    [C] 1 and 2 only

    [D] 1, 2 and 3

  • Centre Brings Advanced Cell & Gene Therapies Under CLAA Framework

    Why in News?

    The Central Government has amended the Drugs Rules, 1945 to bring Cell or Stem Cell-derived products, Gene Therapeutic Products, and Xenografts under the Centrally License Approving Authority (CLAA) framework, ensuring uniform regulation across India.

    What is the Amendment?

    • Expands the CLAA framework to include: Cell or Stem Cell-derived products, Gene therapeutic products and Xenografts.
    • These products will now be subject to joint oversight by the Central and State Licensing Authorities.

    What is the CLAA Framework?

    • Established under the Drugs and Cosmetics Act, 1940.
    • Provides joint regulatory supervision by Central Licensing Authority and State Licensing Authorities.
    • Earlier covered critical biological products such as Vaccines, Large Volume Parenterals (IV solutions >100 ml), and Recombinant DNA (r-DNA)-based medicines.
    • The amendment expands its scope to emerging advanced therapies.

    Emerging Therapies Covered

    1. Cell or Stem Cell-derived Products

    • Therapies developed using stem cells or other living cells.
    • Used in Regenerative medicine. CAR-T cell therapy for blood cancers such as leukemia and lymphoma.

    2. Gene Therapeutic Products

    • Modify or replace defective genes to treat diseases.
    • Include Gene replacement therapy and Gene editing therapies.
    • Used for Genetic disorders and Certain cancers.

    3. Xenografts

    • Animal tissue or organ-derived products transplanted into humans.
    • Examples: Animal-derived heart valves.
    • Applications: Cardiology and Orthopedics.

    Why is the Amendment Important?

    • Ensures uniform regulatory standards across all States.
    • Enhances patient safety through stricter oversight.
    • Strengthens regulation of rapidly evolving medical technologies.
    • Aligns India’s regulatory framework with global best practices.
    • Promotes innovation while ensuring safe adoption of advanced therapies.

    UPSC Prelims Facts

    • CAR-T (Chimeric Antigen Receptor T-cell) therapy is a form of immunotherapy in which a patient’s T-cells are genetically modified to attack cancer cells.
    • Stem cells are undifferentiated cells capable of self-renewal and differentiation into specialized cell types.
    • Gene therapy involves introducing, replacing, or editing genes to treat or prevent diseases.
    • Xenotransplantation refers to transplantation of living cells, tissues, or organs from one species to another, usually from animals to humans.

    [2026] Which of the following statements with regard to genetic medicine is/are correct ?
    1. Genetic medicines correct/compensate for the faulty genes responsible for disease.
    2. Engineered viruses and lipid nanoparticles are used as carriers of the genetic medicine.
    3. Genetic medicines alter the entire DNA sequence.
    Select the answer using the code given below :

    [A] 1 only

    [B] 2 and 3 only

    [C] 1 and 2 only

    [D] 1, 2 and 3

  • India’s First PinS Instrument Approach Procedure for Helicopter Operations

    Why in News?

    India has approved its first Private Point in Space (PinS) Instrument Approach Procedure for helicopter operations at Undavalli Heliport (Andhra Pradesh). The procedure was developed by the Airports Authority of India (AAI) and approved by the Directorate General of Civil Aviation (DGCA).

    What is PinS (Point in Space)?

    • A satellite based instrument approach procedure designed specifically for helicopters.
    • Enables helicopters to fly safely under Instrument Flight Rules (IFR) even when heliports lack conventional landing systems.
    • Uses GNSS/GAGAN enabled Performance Based Navigation (PBN) instead of ground based navigation aids.
    • Developed according to ICAO Standards and Recommended Practices (SARPs).

    How does PinS work?

    • Guides helicopters to a predefined Point in Space (PinS) using satellite navigation.
    • From the PinS point, the helicopter either lands visually if weather permits, or continues under instrument guidance where applicable.
    • Improves operations during poor visibility, rain, fog and difficult terrain.

    Significance

    • Enhances aviation safety and operational reliability.
    • Enables all weather helicopter connectivity.
    • Improves access to remote, hilly and strategically important locations.
    • Reduces dependence on expensive ground based navigation infrastructure.
    • Supports: Emergency Medical Services (EMS), Disaster relief operations, Char Dham and other pilgrimage services, Tourism, Offshore oil and gas operations, Corporate aviation, and Regional connectivity under UDAN.

    Instrument Flight Rules (IFR)

    • Flight operations conducted primarily using cockpit instruments rather than visual references.
    • Essential during poor weather and low visibility.

    Performance Based Navigation (PBN)

    • Navigation based on aircraft performance standards using satellite navigation.
    • Improves route efficiency, safety and fuel savings.

    GAGAN (GPS Aided GEO Augmented Navigation)

    • India’s Satellite Based Augmentation System (SBAS).
    • Developed jointly by ISRO and AAI.
    • Enhances the accuracy and integrity of GPS signals for civil aviation.

    [2025] GPS-Aided Geo Augmented Navigation (GAGAN) uses a system of ground stations to provide necessary augmentation. Which of the following statements is/are correct in respect of GAGAN?
    I. It is designed to provide additional accuracy and integrity.
    II. It will allow more uniform and high quality air traffic management.
    III. It will provide benefits only in aviation but not in other modes of transportation.
    Select the correct answer using the code given below.

    [A] I, II and III

    [B] II and III only

    [C] I only

    [D] I and II only

  • [1st July 2026] The Hindu OpED: Reimagining sovereign AI for India’s strategic future 

    Mentor’s Comment

    The United States government directed Anthropic to suspend foreign national access to its Fable 5 and Mythos 5 AI models on national security grounds, and is separately considering equity stakes in leading AI companies. At the same time, India lacks frontier AI capability of its own and must rely on foreign models to remain competitive. This dependence carries geopolitical risk that neither market competition nor inter-ministerial coordination alone can resolve.

    What explains the global turn toward sovereign AI policymaking, and why does India need a coordinated response?

    1. US export controls: The US suspended foreign national access to Anthropic’s Fable 5 and Mythos 5 models on national security grounds and created a voluntary mechanism for federal government access up to 30 days before trusted partners.
    2. Equity stake consideration: The US administration is considering taking equity stakes in leading AI firms to capture a share of the supernormal profits expected from the technology.
    3. Global pattern: Governments are increasingly shaping AI policy around national advantage rather than leaving diffusion purely to markets.
    4. India’s structural gap: India is a large IT services economy without its own frontier AI systems (Frontier AI: AI systems requiring upwards of ten septillion floating-point operations to train).
    5. Reason for urgency: Policy decisions made elsewhere increasingly determine the terms on which India can access frontier technology, making a coherent domestic response necessary now.

    Why is India’s AI policy discourse trapped in a false binary, and why must this framing be rejected?

    1. The dependence dilemma: India’s IT and app companies must use the best available foreign AI to remain competitive, yet this use deepens dependence on models built abroad.
    2. Sequencing logic: Using foreign AI today builds the economic surplus needed to depend on it less in future. Diffusion and dependence-reduction are sequential goals, not opposed ones.
    3. Limits of firm-level action: Firms can outcompete rivals using foreign AI. Firms cannot manage the geopolitical risks that accompany dependence on it. That risk-management role falls to public policy.
    4. False binary named: India’s discourse frames globalisation and industrial policy as mutually exclusive. Indian industry must benefit from both at the same time.
    5. Pharma precedent: Indian pharmaceutical manufacturing shows the limits of industrial policy alone. A Production-Linked Incentive (PLI: a government scheme offering incentives tied to incremental domestic manufacturing output) promoted domestic bulk drug production. India still sources 65% of critical ingredients from China, per NITI Aayog’s latest assessment.
    6. Implication: Industrial policy creates footholds. It does not create instant resilience. This sets the correct expectation for AI policy as well.

    What institutional architecture should India build to benefit from frontier AI without deepening strategic dependence?

    1. Scale of the gap: India spends 0.6% of GDP on research and development, of which the private sector accounts for a third. OpenAI alone projects $50 billion in compute spending this year, over six times India’s annual private R&D spend.
    2. Strategic implication: India cannot outspend frontier AI investment. India must instead deepen backward linkages to frontier AI while strengthening forward linkages for its own products and services.
    3. Whole-of-government approach: Ministries of external affairs, commerce, and information technology must coordinate closely. Coordination should extend to defence, energy, and telecom where relevant.
    4. Objective of coordination: The architecture secures continued access to frontier AI inputs. It simultaneously builds global market access for Indian AI-enabled products and services.

    Since coordination alone cannot manage geopolitical risk, what role must the state play in underwriting it?

    1. Limits of firm-level risk management: Firms can manage commercial risk through contracts and diversified supply chains. Firms cannot insure themselves against geopolitical risk or concentrated technological dependence.
    2. Sovereign risk-bearing role: Underwriting such risk is a function only the state can perform. Private capital cannot efficiently bear this risk alone.
    3. Export credit analogy: Export credit mechanisms insure firms against risks they cannot shoulder independently in international trade, offering a template for AI-related risk underwriting.
    4. Hybrid-annuity analogy: The Hybrid-Annuity Model (HAM: an infrastructure financing structure where the state funds part of a project and makes fixed payments over time) reduces the share of risk borne by private capital in long-gestation infrastructure. A comparable approach could apply to frontier AI dependence.

    What do the available global examples suggest about alternative sovereign AI strategies? 

    1. Europe: Shifted from a “regulate first, ask questions later” approach to investing directly in AI compute capacity and promoting “Buy European” public procurement to support its domestic AI industry.
    2. Argentina: Is positioning itself to attract AI investment by offering a regulatory safe harbour under an accommodative regulatory posture.

    Why must India’s technology industry itself close the competitiveness gap, and what does this reveal about the limits of policy alone?

    1. Government’s limits: Government action can create conditions for success. Competitiveness must ultimately come from firms themselves.
    2. Export benchmark: The Philippines generates $40 billion in IT exports, nearly a sixth of India’s IT exports, and is growing faster than the global industry.
    3. App market underperformance: No Indian app features among the top 10 globally by downloads, in-app purchase revenue, or monthly active users.
    4. Fragmented industry voice: Incumbent IT firms remain focused on visas and market access. Startups remain consumed by regulatory friction and fundraising. Both share a common interest in India’s continued connection to global AI ecosystems alongside growing domestic capability.
    5. Core stakes: The central contest in AI is not only over who builds the best models. It is over who captures the economic and strategic advantages the models create.

    Conclusion

    India’s AI strategy must reject the false choice between global integration and domestic capability building. The objective is to remain deeply integrated with global AI ecosystems while steadily reducing the strategic vulnerabilities such integration creates. This requires backward linkages secured through whole-of-government coordination, forward linkages built through competitive Indian products and services, and state-backed risk underwriting on the export-credit and hybrid-annuity model. Without matching ambition from industry itself, government action alone cannot close the gap.

  • [30th June 2026] The Hindu OpED: Why artificial wisdom is the biggest AI risk

    PYQ Relevance[UPSC 2023] Introduce the concept of Artificial Intelligence (AI). How does AI help clinical diagnosis? Do you perceive any threat to privacy of the individual in the use of AI in healthcare?
    Linkage: The PYQ tests understanding of AI’s applications alongside ethical concerns such as privacy, accountability and responsible deployment. The article extends the debate beyond privacy to examine AI-generated misinformation, concentration of AI power, the limits of machine-generated knowledge, and the need for robust AI governance and regulation.

    Mentor’s Comment

    AI debates have centred on job losses and concentration of power among a few firms and nations. A third, less discussed risk is emerging: AI is being treated as a substitute for human cognition, even though it produces information, not knowledge. The conflation of AI output with genuine knowledge has no such precedent and currently has no accountability structure attached to it.

    Why are labour displacement and power concentration considered the more manageable AI risks?

    1. Historical precedent on labour: Technology has automated specific tasks, not entire professions; the steam engine displaced labour into new industries rather than eliminating it.
    2. Expected AI trajectory: Some occupations will shrink, others will expand, and new professions will emerge, mirroring past transitions.
    3. Transition cost is real: The shift will require substantial investment in reskilling, but is not existential.
    4. Capital-intensive economics of AI: Frontier models require massive investment in computing infrastructure, energy, talent and data, restricting ownership to a few firms and countries.
    5. Concentration risk has known parallels: Concentrated control of strategic resources such as gold or oil has historically produced geopolitical leverage and coercive behaviour.
    6. Institutional tools already exist: Legal institutions, international treaties and negotiated frameworks have managed comparable concentration risks before.

    What is the curse of “artificial wisdom” and why is it the most dangerous AI risk?

    1. Core misconception: AI enthusiasts position AI as a substitute for human cognition, leading society to internalise the belief that AI generates knowledge.
    2. What AI actually does: An AI system is trained on data to learn patterns and statistical relationships, and predicts the most probable next step in a sequence.
    3. Knowledge versus information: Information is what AI produces; Knowledge: understanding that requires context, judgment, experience and an understanding of consequences.
    4. Verification requires expertise: Only a human mind with domain expertise can judge whether AI-generated output is useful and appropriate for a given problem.
    5. Why this risk is least understood: It is structurally different from labour and power risks because it changes how truth itself is assessed, not just who holds resources or jobs.

    How does the information-knowledge conflation translate into systemic harm?

    1. Synthetic information advantage: AI-generated content can be more persuasive, accessible or appealing than genuine information.
    2. Erosion of fact-fabrication distinction: Individuals and institutions struggle to separate fact from fabrication, creating conditions for manipulation and misinformation.
    3. Organisational dependence: Organisations increasingly use AI for research, coding, legal drafting and financial analysis.
    4. Unverifiable decision-making: This creates systemic risk because decisions are influenced by intelligence that nobody is qualified to verify.
    5. Paradox of expertise: The AI age makes genuine domain expertise more valuable, since the rarest skill becomes determining whether machine-generated answers are correct.

    Why does AI’s accountability gap require a new governance architecture?

    1. Existing liability model: Manufacturers of harmful pharmaceutical products can be held accountable under established liability law.
    2. AI’s liability gap: AI systems have largely operated without comparable clear liability.
    3. Emerging accountability signal: Meta Platforms has faced lawsuits alleging that its platform design contributed to harm among young users, indicating accountability boundaries are beginning to be redrawn for digital platforms.
    4. Proposed safeguard structure: The response requires both technical and institutional safeguards, backed by a global non-proliferation agreement on disruptive AI.
    5. Containment objective: Such an agreement must allow humans to limit or shut down AI systems operating outside their intended boundaries.
    6. Precedent for restraint: Humanity has avoided nuclear catastrophe for eight decades; AI governance is framed as a comparable challenge of sustained, deliberate restraint.

    Conclusion

    The defining AI risk is not job loss or concentrated ownership, both of which have historical management precedents. It is the unchecked substitution of AI-generated information for genuine knowledge, compounded by the absence of liability and verification structures. Closing this gap requires a global governance architecture combining technical safeguards, institutional accountability, and a non-proliferation framework for disruptive AI capabilities, built before reliance on unverified AI output becomes irreversible.

  • What India’s 12 ‘operationally deployed’ nuclear warheads mean

    Why in the News?

    SIPRI’s 2026 Yearbook classified 12 of India’s 190 nuclear warheads as operationally deployed for the first time. These are positioned with active military forces mated with delivery systems and ready for use.The classification has triggered concern over a possible shift in India’s No First Use (NFU) doctrine.

    Why does SIPRI’s “deployment” classification not indicate a shift in India’s nuclear doctrine?

    1. No change in launch policy: NFU commits India to not launching a pre-emptive strike; SIPRI’s report records no revision of this commitment.
    2. No threshold lowering: The report does not indicate any lowering of the threshold for nuclear employment.
    3. No change in political control: Civilian and political oversight mechanisms governing nuclear release remain unaltered.
    4. Expert confirmation: Warheads mated with delivery platforms make assured retaliation more credible, not less restrained.
    5. Reaffirmed commitment: India’s representatives reaffirmed NFU and non-use against non-nuclear-weapon states at the UN High-Level Meeting in September 2025.
    6. Internal calls for first-use rejected: Periodic domestic proposals for a conditional or hybrid first-use posture have not prevailed.

    Why does the stockpile-deployment distinction matter for assessing India’s posture?

    Possessing a warhead and deploying it as part of an operational deterrent are not the same condition. The distinction determines whether a count of warheads signals readiness or merely holdings.

    1. De-mated baseline: For most of its nuclear history, India stored warheads separately from delivery vehicles at a central site under strict oversight.
    2. Purpose of de-mating: This was meant to maximise safety, reduce accidental-use risk, and signal restraint internationally.
    3. Definition of deployment: Deployment pairs a warhead with a delivery system and positions it with operational forces in readiness.
    4. Readiness, not intent: A deployed weapon is configured for use if authorised; it is not a signal of imminent use.
    5. Speed differential: A de-mated weapon needs time to prepare and deploy; a mated weapon can be launched faster.
    6. Scale of the shift: SIPRI’s count reflects a small but significant fraction of India’s arsenal now held in operational readiness, not a wholesale change in posture.

    How does the sea-based deterrent resolve the central vulnerability in India’s NFU doctrine?

    NFU is a retaliation-only doctrine, so it stands or falls on whether the force can survive a first strike. Sea-basing closes the specific gap that land-based deployment cannot.

    1. Survivability requirement: NFU depends on enough of the arsenal surviving a first strike to deliver a retaliatory blow; without this, NFU becomes a liability rather than a doctrine.
    2. Land-based vulnerability: Land-based missiles sit at known, mappable locations and can be targeted in a disarming first strike.
    3. Sea-based advantage: A submerged submarine cannot be found, tracked, or destroyed in time, removing this vulnerability.
    4. Arihant-class platform: India’s Arihant-class submarines have steadily strengthened second-strike survivability, with additional platforms expected to further consolidate this leg of the triad.
    5. Operational milestone: Three operational SSBNs allow India to keep at least one submarine submerged and on patrol at all times.
    6. Supporting readiness measure: Increasing reliance on canisterised Agni-series missiles, which carry fuel sealed and ready, raises operational readiness without requiring further preparation before launch.

    What broader trend does India’s deployment milestone sit within, and why does it matter?

    1. Global reversal: SIPRI’s 2026 Yearbook records states increasingly relying on nuclear weapons as instruments of national power, reversing decades of gradual disarmament progress.
    2. Scale of global arsenals: Nine nuclear-armed states held an estimated 12,187 warheads as of January 2026.
    3. China’s pace: China’s arsenal has grown to approximately 620 warheads, expanding faster than any other nuclear power and now over three times Pakistan’s estimated stockpile.
    4. Dual-direction posture: India’s modernisation is increasingly focused on long-range systems capable of reaching China, while continuing to account for Pakistan.
    5. Weakening arms control: Arms-control agreements have weakened or collapsed even as competition intensifies in hypersonic delivery, AI-enabled decision support, missile defence, and anti-submarine warfare.
    6. Unresolved risk: The maturation of India’s second-strike capability strengthens deterrence bilaterally, but does nothing to address the rising risk of miscalculation across a destabilising global order.

    Conclusion

    SIPRI’s classification of 12 Indian warheads as operationally deployed documents the maturing of India’s sea-based second-strike capability, not a retreat from No First Use. This development, however, sits inside a global environment where arms-control frameworks are weakening and major powers are re-arming. The institutions designed to manage nuclear risk must adapt to this faster-fielding environment, or the credibility gained through India’s improved deterrent will be offset by a rising structural risk of miscalculation.

    PYQ Relevance

    [UPSC 2017] Give an account of the growth and development of nuclear science and technology in India. What is the advantage of fast breeder reactor programme in India?

    Linkage: Tests India’s strategic nuclear capabilities, indigenous nuclear development and the evolution of its deterrence architecture.The article explains how India’s maturing nuclear triad and operational deployment strengthen its credible minimum deterrence and second-strike capability without altering its No First Use doctrine.

  • Advancing Electrolyte Engineering for Durable and Affordable Aqueous Batteries

    Why in News?

    Scientists at the Institute of Nano Science and Technology (INST), Mohali, under the Department of Science and Technology (DST), have developed a novel electrolyte additive that significantly improves the performance and lifespan of Aqueous Zinc Ion Batteries (AZIBs).

    What are Aqueous Zinc Ion Batteries (AZIBs)?

    • Rechargeable batteries that use zinc metal as the anode and a water-based electrolyte.
    • Considered a promising alternative to lithium-ion batteries because they are Safer (non-flammable electrolyte), Low-cost (abundant zinc), Environment-friendly, and Suitable for large-scale energy storage.

    Challenges in AZIBs

    • Growth of zinc dendrites (needle-like deposits causing short circuits)
    • Hydrogen Evolution Reaction (HER) leading to gas formation
    • Corrosion of zinc anode
    • Poor cycling stability and reduced battery life

    Key Innovation

    • Researchers developed an electrolyte additive called BDIM (1,3-bis(1,3-dicarboxypropyl)-1H-imidazole-3-ium chloride).
    • BDIM selectively adsorbs on the zinc surface and regulates the Inner Helmholtz Plane (IHP).
    • It displaces water molecules from the electrode surface, thereby:
      • Suppressing hydrogen evolution
      • Reducing corrosion
      • Preventing dendrite formation
      • Enhancing battery lifespan and stability

    Important Concepts

    • Electrolyte: A medium containing ions that enables the flow of electric charge between battery electrodes.
    • Inner Helmholtz Plane (IHP): The innermost layer at the electrode-electrolyte interface where electrochemical reactions occur. Controlling this layer improves battery efficiency and durability.
    • Research Techniques Used
      • Ultramicroelectrode (UME): Tiny electrode (<50 µm) enabling high-resolution electrochemical studies.
      • Fast-Scan Cyclic Voltammetry (FSCV): Technique used to study rapid charge-transfer and zinc deposition mechanisms.

    [2025] In the context of electric vehicle batteries, consider the following elements:
    I. Cobalt
    II. Graphite
    III. Lithium
    IV. Nickel
    How many of the above usually make up battery cathodes?

    [A] Only one

    [B] Only two

    [C] Only three

    [D] All the four

  • DAE Inaugurates World’s First Nuclear Heat Based Hydrogen Production Facility

    Why in News?

    The Department of Atomic Energy (DAE) has inaugurated the world’s first hydrogen production facility based on the Copper-Chlorine (Cu-Cl) Thermochemical Cycle using nuclear process heat from the Fast Breeder Test Reactor (FBTR) at Kalpakkam.

    Key Highlights

    • First in the world to produce hydrogen using the Cu-Cl thermochemical cycle powered by nuclear heat.
    • Established at the Indira Gandhi Centre for Atomic Research (IGCAR), Kalpakkam.
    • Uses process heat from the Fast Breeder Test Reactor (FBTR) instead of fossil fuels.
    • Technology developed indigenously by the Bhabha Atomic Research Centre (BARC).
    • Serves as a technology demonstrator for future commercial-scale nuclear hydrogen production.

    What is the Copper-Chlorine (Cu-Cl) Thermochemical Cycle?

    The Cu-Cl cycle is a series of chemical reactions that split water into hydrogen and oxygen using heat and electricity.

    Process

    • Water reacts with copper and chlorine compounds.
    • High-temperature nuclear heat drives most of the reactions.
    • Hydrogen gas is produced while intermediate chemicals are recycled.

    Advantages

    • Operates at lower temperatures (≈500°C) than many other thermochemical cycles.
    • Higher thermodynamic efficiency.
    • Requires less electricity.
    • Produces zero greenhouse gas emissions when powered by nuclear energy.

    Why Use Nuclear Heat?

    • Fast reactors generate both Carbon-free electricity and High-temperature process heat.
    • Using this heat:
      • Reduces dependence on natural gas for hydrogen production.
      • Improves overall reactor efficiency.
      • Enables continuous hydrogen production irrespective of weather conditions.

    Fast Breeder Test Reactor (FBTR)

    • Located at IGCAR, Kalpakkam.
    • India’s only operating fast reactor research facility.
    • Commissioned in 1985.
    • Uses liquid sodium as coolant.
    • Produces plutonium while generating power.

    [2023] Consider the following heavy industries:
    1. Fertilizer plants
    2. Oil refineries
    3. Steel plants
    Green hydrogen is expected to play a significant role in decarbonizing how many of the above industries?

    [A] Only one

    [B] Only two

    [C] All three

    [D] None